{"id":"NCT03125902","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","officialTitle":"A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-25","primaryCompletion":"2019-11-15","completion":"2023-01-17","firstPosted":"2017-04-24","resultsPosted":"2021-01-07","lastUpdate":"2024-03-26"},"enrollment":653,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Triple-Negative Breast Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","otherNames":["MPDL3280A, TECENTRIQ"]},{"type":"DRUG","name":"Atezolizumab Placebo","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"Placebo and Paclitaxel","type":"PLACEBO_COMPARATOR"},{"label":"Atezolizumab and Paclitaxel","type":"EXPERIMENTAL"}],"summary":"This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 \\[PD-L1\\] antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in participants with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC. Participants will be randomized in a 2:1 ratio to receive atezolizumab or placebo plus paclitaxel until disease progression or unacceptable toxicity or end of study, whichever occurs first (maximum up to approximately 40 months). In addition, the Sponsor may decide to terminate the study at any time.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status","timeFrame":"From Day 1 to disease progression (PD) or death from any cause, assessed up to primary completion date (approximately 26 months)","effectByArm":[{"arm":"Placebo and Paclitaxel","deltaMin":5.72,"sd":null},{"arm":"Atezolizumab and Paclitaxel","deltaMin":5.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2032"},{"comp":"OG000 vs OG001","p":"0.2601"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":12},"locations":{"siteCount":161,"countries":["United States","Argentina","Brazil","Canada","China","Croatia","Czechia","France","Germany","Greece","India","Israel","Italy","Japan","Morocco","Romania","Russia","Saudi Arabia","Slovakia","South Africa","Spain","Turkey (TÃ¼rkiye)","United Kingdom","Vietnam"]},"refs":{"pmids":["34219000"],"seeAlso":["https://www.pioneeringhealthcare.com/de/trials/breast-cancer-de/178/impassion131-de/","https://www.wissen-immuntherapie.de/klinische-studien/studien-finden/"]},"adverseEventsSummary":{"seriousAny":{"events":112,"n":431},"commonTop":["ALOPECIA","ANAEMIA","NEUROPATHY PERIPHERAL","DIARRHOEA","FATIGUE"]}}